LGR6 Activators
LGR6 activators encompass a group of chemical compounds that, through various mechanisms, facilitate the activation or increase the expression of LGR6 by modulating the Wnt/β-catenin signaling pathway and associated cellular processes. These compounds act at different levels of the pathway, from the stabilization of β-catenin to the transcriptional regulation of Wnt target genes. Compounds such as CHIR99021, SB-216763, BIO-acetoxime, and LiCl exert their effects by inhibiting GSK-3, a key kinase that, when active, promotes the degradation of β-catenin. By inhibiting GSK-3, these activators ensure the accumulation of β-catenin, which translocates to the nucleus to enhance the expression of Wnt-responsive genes, including those related to LGR6 activation. This results in the indirect upregulation of LGR6 activity due to the augmented transcription and signaling efficiency of Wnt/β-catenin.
Other compounds in this class, such as Forskolin and 6-Bnz-cAMP, raise the levels of cAMP, which subsequently activates PKA. PKA phosphorylates targets within the Wnt pathway, enhancing its responsiveness and thereby indirectly contributing to LGR6 activation. Furthermore, agents like WAY-316606 and SKL2001 directly modulate the components of the Wnt signaling pathway, either by antagonizing pathway inhibitors or by altering the interaction dynamics of β-catenin, thereby facilitating the expression and function of LGR6. In addition, (S)-(+)-Ibuprofen and Valproic Acid, though not typically associated with the Wnt pathway, can affect it through PPARα activation and histone deacetylase inhibition, respectively, illustrating the diverse chemical mechanisms through which LGR6 activity can be indirectly increased. Overall, the activation of LGR6 by these chemicals highlights the intricate regulatory abilities of the Wnt/β-catenin signaling pathway and its pivotal role in the modulation of receptor activity.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Adenylyl cyclase activator Forskolin raises intracellular cAMP levels, which can enhance PKA activity. PKA phosphorylates various targets involved in Wnt signaling, thus Forskolin indirectly facilitates LGR6 activation by promoting Wnt pathway responsiveness through increased β-catenin transcriptional activity. | ||||||
Wnt Synergist, QS11 | 944328-88-5 | sc-222417 sc-222417A | 5 mg 25 mg | $141.00 $607.00 | ||
GTPase-activating protein of ADP-ribosylation factor 1 (ARFGAP1) inhibitor QS11 impedes the Wnt/β-catenin pathway's degradation complex, thus stabilizing β-catenin. Stabilized β-catenin upregulates LGR6 expression by enhancing transcription of Wnt-responsive genes. | ||||||
SB-216763 | 280744-09-4 | sc-200646 sc-200646A | 1 mg 5 mg | $71.00 $202.00 | 18 | |
This GSK-3 inhibitor, similar to CHIR99021, stabilizes β-catenin, facilitating its nuclear translocation and subsequent promotion of Wnt target gene expression. This action increases LGR6 protein levels, thereby indirectly potentiating its activation. | ||||||
Adenosine 3′,5′-cyclic Monophosphate, N6-Benzoyl-, Sodium Salt | 30275-80-0 | sc-300167 | 10 µmol | $324.00 | 1 | |
A cAMP analog that selectively activates PKA. 6-Bnz-cAMP's activation of PKA leads to phosphorylation events that bolster Wnt/β-catenin pathway efficiency, ultimately upregulating LGR6 expression and activity through improved transcriptional regulation of its gene. | ||||||
SKL2001 | 909089-13-0 | sc-507410 | 10 mg | $123.00 | ||
An activator of Wnt/β-catenin signaling, SKL2001 disrupts the interaction between β-catenin and its negative regulator APC, leading to increased β-catenin-driven transcription. This supports the expression of LGR6 by amplifying the signaling output of the Wnt/β-catenin pathway. | ||||||
(S)-Ibuprofen | 51146-56-6 | sc-200612 sc-200612A | 1 g 5 g | $48.00 $143.00 | 4 | |
While primarily known as a nonsteroidal anti-inflammatory drug, (S)-(+)-Ibuprofen can also activate PPARα, a nuclear receptor that, upon activation, can interact with β-catenin, enhancing Wnt signaling and potentially increasing the transcription and activity of LGR6. | ||||||
PNU-74654 | 113906-27-7 | sc-258020 sc-258020A | 5 mg 25 mg | $131.00 $495.00 | 7 | |
A compound that disrupts the interaction between β-catenin and TCF, PNU-74654 indirectly stimulates the Wnt signaling pathway by preventing β-catenin from being sequestered by TCF. Enhanced free β-catenin levels allow for greater transcriptional activation of Wnt target genes, thereby increasing the expression of LGR6. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium chloride inhibits GSK-3β, leading to the accumulation of β-catenin in the cytoplasm and its subsequent translocation into the nucleus to promote Wnt target gene expression, which includes the gene coding for LGR6, thus indirectly promoting its activity. | ||||||
Valproic Acid | 99-66-1 | sc-213144 | 10 g | $87.00 | 9 | |
Histone deacetylase inhibitor that can modulate gene expression profiles. By altering chromatin structure and thus gene expression, Valproic Acid can enhance the Wnt/β-catenin signaling pathway, which in turn could result in increased expression and activity of LGR6 by promoting transcription of genes within this pathway, including LGR6 itself. | ||||||